New combo therapy shows promise for tough liver cancer cases
NCT ID NCT06881433
First seen May 16, 2026 · Last updated May 16, 2026
Summary
This study tested whether adding a liver-directed chemotherapy infusion (HAIC) to standard drug therapy (immunotherapy plus anti-angiogenesis drugs) improves survival in people with advanced liver cancer that has spread into the main blood vessel of the liver. Over 1,600 participants were included. The goal was to see if the triple combination could help patients live longer and keep the cancer from growing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhongda Hospital
Nanjing, Jiangsu, China
Conditions
Explore the condition pages connected to this study.